Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SynAct Pharma AB ( (SE:SYNACT) ) has provided an announcement.
SynAct Pharma AB has made significant progress in its Phase 2b ADVANCE study for Resomelagon, a treatment for Rheumatoid Arthritis, by randomizing 190 out of 240 patients. The study aims to evaluate the efficacy of Resomelagon in combination with methotrexate therapy, potentially offering a safer and effective alternative to current treatments, which could impact the future management of Rheumatoid Arthritis, a condition projected to affect up to 32 million people by 2050.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company that specializes in resolving inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, aiding patients in achieving immune balance and overcoming inflammation.
YTD Price Performance: 169.94%
Average Trading Volume: 182,583
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.29B
Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.